Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter N Morcos

Showing results (21-30 of 58) with videos related to

Pageof 6
Sort By:
British Journal of Clinical Pharmacology|October 8, 2014
Pharmacokinetics and safety of oseltamivir in patients with end-stage renal disease treated with automated peritoneal dialysisKashyap Patel, Craig R Rayner, Mylène Giraudon, et al.
Drugs in R&D|March 7, 2015
Effect of a modified saquinavir/ritonavir dosing regimen with lower dose lead-in phase on QTc interval, pharmacokinetics, antiviral activity and safety in treatment-naïve HIV-1-infected patientsMarta Boffito, Akil Jackson, Anton Pozniak, et al.
Clinical and Translational Science|December 14, 2025
No Effect of Immunogenicity on Pharmacokinetics, Efficacy, and Safety of the Oligonucleotide Telomerase Inhibitor Imetelstat in Lower-Risk Myelodysplastic SyndromesAshley L Lennox, Fei Huang, Mario González-Sales, et al.
The Journal of Pharmacy and Pharmacology|October 15, 2013
Effect of meal and antisecretory agents on the pharmacokinetics of danoprevir/ritonavir in healthy volunteersPeter N Morcos, Sebastian A Moreira, Mercidita T Navarro, et al.
European Journal of Clinical Pharmacology|July 23, 2013
A randomised study of the effect of danoprevir/ritonavir or ritonavir on substrates of cytochrome P450 (CYP) 3A and 2C9 in chronic hepatitis C patients using a drug cocktailPeter N Morcos, Linda Chang, Rohit Kulkarni, et al.
Clinical Pharmacology in Drug Development|May 4, 2016
Identification of new oral dosing regimens for the neuraminidase inhibitor oseltamivir in patients with moderate and severe renal impairmentMohamed A Kamal, Barbara J Brennan, Vishak Subramoney, et al.
Clinical Pharmacokinetics|December 10, 2014
Characterization of the transmembrane transport and absolute bioavailability of the HCV protease inhibitor danoprevirBarbara J Brennan, Agnès Poirier, Sebastian Moreira, et al.
Clinical Pharmacokinetics|May 29, 2013
Pharmacokinetics of a three-way drug interaction between danoprevir, ritonavir and the organic anion transporting polypeptide (OATP) inhibitor ciclosporinBarbara J Brennan, Sebastian A Moreira, Peter N Morcos, et al.
Journal of Clinical Pharmacology|July 28, 2018
Effect of Hepatic Impairment on the Pharmacokinetics of AlectinibPeter N Morcos, Yumi Cleary, Carolina Sturm-Pellanda, et al.
Cancer Chemotherapy and Pharmacology|March 1, 2017
Effect of alectinib on cardiac electrophysiology: results from intensive electrocardiogram monitoring from the pivotal phase II NP28761 and NP28673 studiesPeter N Morcos, Katrijn Bogman, Stanislas Hubeaux, et al.
Pageof 6

Showing results (21-30 of 58) with videos related to

Sort By:
Pageof 6
British Journal of Clinical Pharmacology|October 8, 2014
Pharmacokinetics and safety of oseltamivir in patients with end-stage renal disease treated with automated peritoneal dialysisKashyap Patel, Craig R Rayner, Mylène Giraudon, et al.
Drugs in R&D|March 7, 2015
Effect of a modified saquinavir/ritonavir dosing regimen with lower dose lead-in phase on QTc interval, pharmacokinetics, antiviral activity and safety in treatment-naïve HIV-1-infected patientsMarta Boffito, Akil Jackson, Anton Pozniak, et al.
Clinical and Translational Science|December 14, 2025
No Effect of Immunogenicity on Pharmacokinetics, Efficacy, and Safety of the Oligonucleotide Telomerase Inhibitor Imetelstat in Lower-Risk Myelodysplastic SyndromesAshley L Lennox, Fei Huang, Mario González-Sales, et al.
The Journal of Pharmacy and Pharmacology|October 15, 2013
Effect of meal and antisecretory agents on the pharmacokinetics of danoprevir/ritonavir in healthy volunteersPeter N Morcos, Sebastian A Moreira, Mercidita T Navarro, et al.
European Journal of Clinical Pharmacology|July 23, 2013
A randomised study of the effect of danoprevir/ritonavir or ritonavir on substrates of cytochrome P450 (CYP) 3A and 2C9 in chronic hepatitis C patients using a drug cocktailPeter N Morcos, Linda Chang, Rohit Kulkarni, et al.
Clinical Pharmacology in Drug Development|May 4, 2016
Identification of new oral dosing regimens for the neuraminidase inhibitor oseltamivir in patients with moderate and severe renal impairmentMohamed A Kamal, Barbara J Brennan, Vishak Subramoney, et al.
Clinical Pharmacokinetics|December 10, 2014
Characterization of the transmembrane transport and absolute bioavailability of the HCV protease inhibitor danoprevirBarbara J Brennan, Agnès Poirier, Sebastian Moreira, et al.
Clinical Pharmacokinetics|May 29, 2013
Pharmacokinetics of a three-way drug interaction between danoprevir, ritonavir and the organic anion transporting polypeptide (OATP) inhibitor ciclosporinBarbara J Brennan, Sebastian A Moreira, Peter N Morcos, et al.
Journal of Clinical Pharmacology|July 28, 2018
Effect of Hepatic Impairment on the Pharmacokinetics of AlectinibPeter N Morcos, Yumi Cleary, Carolina Sturm-Pellanda, et al.
Cancer Chemotherapy and Pharmacology|March 1, 2017
Effect of alectinib on cardiac electrophysiology: results from intensive electrocardiogram monitoring from the pivotal phase II NP28761 and NP28673 studiesPeter N Morcos, Katrijn Bogman, Stanislas Hubeaux, et al.
Pageof 6